This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Giaccone, G. Search for Related Content PubMed PubMed Citation Articles by Giaccone, G. Related Collections Clinical Research Clinical Research: Clinical Trials

The Potential of Antiangiogenic Therapy in Non–Small Cell Lung Cancer

Author's Affiliation: Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands

Requests for reprints: Giuseppe Giaccone, Department of Medical Oncology, VU University Medical Center, 1007 MB Amsterdam, the Netherlands. Phone: 31-20-444-4352; Fax: 31-20-444-4079; E-mail: G.Giaccone{at}vumc.nl.

The long-term prognosis for patients with advanced non–small cell lung cancer (NSCLC) remains poor despite the availability of several cytotoxic chemotherapy regimens. The use of targeted therapies, particularly those against the key mediator of angiogenesis vascular endothelial growth factor (VEGF), has the potential to improve outcomes for NSCLC patients. Bevacizumab, a recombinant humanized monoclonal anti-VEGF antibody, is the most clinically advanced antiangiogenic agent in NSCLC. In a phase III study, bevacizumab showed significantly improved overall and progression-free survival when used in combination with standard first-line chemotherapy in patients with advanced NSCLC. Bevacizumab was generally well tolerated in patients with NSCLC; however, tumor-related bleeding adverse events have been noted in some patients, predominantly those with squamous cell histology or centrally located tumors. Several small-molecule VEGF receptor tyrosine kinase inhibitors have also shown promise in phase I and II trials in NSCLC. This review summarizes the most important findings of angiogenesis inhibitors in NSCLC and discusses the potential for the use of these novel agents in different settings of NSCLC.

This article has been cited by other articles:

				G. Philippin-Lauridant, S. Thureau, M.-J. Ouvrier, and E. Blot Fatal hemoptysis in a patient with breast cancer treated with bevacizumab and paclitaxel Ann. Onc., November 1, 2008; 19(11): 1977 - 1978. [Full Text] [PDF]

				G. C. Prendergast This month in Cancer Reviews Online: Cancer risk factors, progression mechanisms, and targeted drug studies Cancer Reviews Online Content, May 1, 2007; 2007(2): 3 - 4. [Full Text] [PDF]